Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

DiNardo

Showing results (991-1000 of 1,482) with videos related to

Pageof 149
Sort By:
The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.
Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
Blood|May 4, 2013
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemiaCourtney D DiNardo, Kathleen J Propert, Alison W Loren, et al.
The Lancet. Microbe|June 6, 2022
CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics studyZhen Huang, Sylvia M LaCourse, Alexander W Kay, et al.
JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|January 28, 2026
Host- and pathogen-related determinants of pulmonary <i>versus</i> extrapulmonary tuberculosisBegna Tulu, Thomas Theo Brehm, Reinout van Crevel, et al.
Journal of Hematology & Oncology|June 17, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasmsSankalp Arora, Jayastu Senapati, Indraneel Deshmukh, et al.
Haematologica|July 2, 2026
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemiaThura Win Htut, Jeannot Kekedjian, Nicholas Short, et al.
American Journal of Hematology|October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agentsNicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
Pageof 149

Showing results (991-1000 of 1,482) with videos related to

Sort By:
Pageof 149
The Lancet. Haematology|August 12, 2019
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyFarhad Ravandi, Rita Assi, Naval Daver, et al.
Blood Advances|November 2, 2022
Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AMLGhayas C Issa, Aram Bidikian, Sangeetha Venugopal, et al.
Blood|May 4, 2013
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemiaCourtney D DiNardo, Kathleen J Propert, Alison W Loren, et al.
The Lancet. Microbe|June 6, 2022
CRISPR detection of circulating cell-free Mycobacterium tuberculosis DNA in adults and children, including children with HIV: a molecular diagnostics studyZhen Huang, Sylvia M LaCourse, Alexander W Kay, et al.
JCO Oncology Practice|July 16, 2024
Outcomes of Patients With Newly Diagnosed AML and HyperleukocytosisFadi G Haddad, Koji Sasaki, Jayastu Senapati, et al.
Hemasphere|January 19, 2026
Highly effective combination of BRG1/BRM inhibitor with BET inhibitor or decitabine for high-risk MECOM-rearranged AMLWarren Fiskus, Christopher P Mill, Jessica Piel, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|January 28, 2026
Host- and pathogen-related determinants of pulmonary <i>versus</i> extrapulmonary tuberculosisBegna Tulu, Thomas Theo Brehm, Reinout van Crevel, et al.
Journal of Hematology & Oncology|June 17, 2026
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasmsSankalp Arora, Jayastu Senapati, Indraneel Deshmukh, et al.
Haematologica|July 2, 2026
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemiaThura Win Htut, Jeannot Kekedjian, Nicholas Short, et al.
American Journal of Hematology|October 18, 2018
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agentsNicholas J Short, Elias Jabbour, Kiran Naqvi, et al.
Pageof 149